SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has reported a strong start to 2025 with notable revenue and profit gains in the first quarter, signaling resilience amid global trade complexities and bolstering its long-term value proposition through innovation and strategic acquisitions.

The company achieved a 3% year-over-year increase in total revenue to $4.8 billion, with organic revenue growth reaching 4%. Net income rose to $564 million from $374 million a year earlier, pushing the net income margin to 11.8%, up from 8.0%. Adjusted EBIT margin also improved slightly to 15.0%, reflecting strong operational execution and productivity improvements.

Strong Performance Across Key Financial Indicators

SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has announced a strategic expansion of its radiation oncology solutions, unveiling a suite of AI-driven technologies at the ESTRO 2025 Congress in Vienna, Austria. These developments are designed to streamline oncology workflows, accelerate treatment timelines, and improve clinical outcomes—addressing critical priorities in modern cancer care.

With cancer continuing to rank among the world’s leading causes of death, GE HealthCare is positioning itself at the forefront of oncology innovation. The company’s new solutions—ranging from AI-enabled organ segmentation to advanced MR-only radiotherapy workflows—aim to equip clinicians with tools that improve efficiency, precision, and personalization in treatment planning.

Strategic Portfolio Expansion with Spectronic Medical Acquisition

SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Aurora dual-head SPECT/CT system and Clarify DL, a Deep Learning-powered image reconstruction solution. This milestone underscores GE HealthCare’s commitment to advancing nuclear medicine by offering solutions that drive diagnostic precision, streamline workflows, and support evolving clinical needs.

University Hospitals in Cleveland, Ohio, has become the first healthcare system in the United States to install the Aurora system. This strategic deployment reflects growing demand among providers for scalable imaging technologies that support a wide range of clinical applications while enabling a more personalized approach to patient care.

SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers has introduced its Magnetom Flow RT Pro Edition at the European Society for Radiotherapy and Oncology (ESTRO) 2025, marking a significant innovation in magnetic resonance imaging (MRI) tailored for radiation therapy. Designed for operational flexibility and clinical precision, the 1.5 Tesla system addresses longstanding challenges in integrating MRI within radiation oncology environments while offering sustainability and workflow advantages.

Revolutionizing MRI Accessibility in Radiotherapy Settings

SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers and Klinikum Region Hannover (KRH) have jointly launched an advanced Infection Control System (ICS) at KRH Klinikum Siloah, a leading regional hospital in Hannover, Germany. The strategic implementation marks a significant move toward reducing hospital-acquired infections (HAIs), improving hygiene standards, and safeguarding both patient and staff well-being across the facility.

Combatting Nosocomial Infections with Innovation

Hospital-acquired infections continue to place immense strain on healthcare systems worldwide. In Germany alone, the Robert Koch Institute reported approximately 600,000 nosocomial infections in 2019, with around 20,000 associated deaths. Multi-resistant germs—responsible for a substantial share of such infections—led to an estimated five million global deaths in 2021. The World Health Organization anticipates this number could double by 2050.

SHERIDAN, WYOMING – May 5, 2025 – Tower Health and Siemens Healthineers have entered a decade-long Value Partnership designed to modernize diagnostic imaging capabilities, enhance operational efficiency, and support long-term clinical excellence across the Tower Health network. The multi-faceted alliance marks a strategic investment in state-of-the-art technology and digital tools aimed at elevating patient care in radiology, oncology, and cardiology services.

Driving Long-Term Value Through Technological Modernization

The 10-year Value Partnership is more than a procurement agreement; it is a strategic roadmap to elevate Tower Health’s infrastructure through lifecycle management and standardization of advanced imaging equipment. The collaboration will bring cutting-edge Siemens Healthineers solutions to Tower Health, including:

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced encouraging 3-month results from its pivotal Omny-IRE clinical trial, spotlighting the high-performance capabilities of its investigational OMNYPULSE™ Platform. Unveiled during the 2025 Heart Rhythm Society (HRS) Annual Meeting and simultaneously published in JACC Clinical Electrophysiology, the findings mark a strategic milestone in the company’s pulsed field ablation (PFA) portfolio expansion, with significant implications for patient care, procedural efficiency, and technology adoption in electrophysiology.

Breakthrough Results from the Omny-IRE Trial

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space. The company’s expansive dataset highlights innovation in pulsed field ablation (PFA) technologies, real-world treatment strategies, and critical insights from the REAL-AF Registry and Patient Care Pathways and Outcomes study—reinforcing its commitment to evidence-based care and better patient outcomes.

Driving Strategic Innovation in Cardiac Electrophysiology

SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has marked a significant milestone in the evolution of robotic-assisted surgery by completing the first clinical trial cases of its OTTAVA™ Robotic Surgical System. This development positions the company at the forefront of innovation in minimally invasive procedures, reinforcing its strategic commitment to delivering cutting-edge surgical technologies that raise standards in operating rooms worldwide.

Strategic Leap in Robotic-Assisted Surgery

The inaugural clinical cases for the OTTAVA system were led by Dr. Erik Wilson, Chief of Minimally Invasive and Elective General Surgery at UT Health Houston, who performed Roux-en-Y gastric bypass surgeries at Memorial Hermann-Texas Medical Center. These procedures represent the first real-world clinical application of the OTTAVA system and a pivotal moment in its developmental journey.

SHERIDAN, WYOMING – May 5, 2025 – Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in circulatory restoration, has officially initiated its FORWARD CAD Investigational Device Exemption (IDE) study. This pivotal research effort will evaluate the safety and efficacy of the Shockwave Javelin Coronary IVL Catheter for the treatment of difficult-to-cross, heavily calcified coronary artery lesions—an area with high unmet clinical need and procedural risk.

The first patient in the study was successfully treated by Dr. Evan Shlofmitz and Dr. Ziad Ali at St. Francis Hospital & The Heart Center in Roslyn, New York. This milestone underscores the growing clinical interest in Shockwave’s forward IVL (intravascular lithotripsy) platform as a potential alternative to atherectomy, especially in complex percutaneous coronary interventions (PCI).

Advancing Treatment for Challenging Coronary Artery Disease